^
BIOMARKER:
KMT2D mutation
i
Other names: KMT2D, Lysine Methyltransferase 2D, Histone-Lysine N-Methyltransferase 2D, Myeloid/Lymphoid Or Mixed-Lineage Leukemia 2, Lysine (K)-Specific Methyltransferase 2D, Trinucleotide Repeat Containing 21, Lysine N-Methyltransferase 2D, ALL1-Related Protein, MLL2, MLL4, ALR, Myeloid/Lymphoid Or Mixed-Lineage Leukemia Protein, Histone-Lysine N-Methyltransferase MLL2, Truncated Lysine Methyltransferase 2D, Kabuki Mental Retardation Syndrome, Kabuki Make-Up Syndrome, CAGL114, KABUK1, TNRC21, AAD10
Entrez ID:
Related biomarkers:
KMT2D mutation
SCCHN
durvalumab + CP-675206
Sensitive
:
B
KMT2D mutation
Follicular Lymphoma
R-CHOP
Resistant
:
C3
KMT2D mutation
Diffuse Large B Cell Lymphoma
chidamide
Resistant
:
C3
KMT2D mutation
Diffuse Large B Cell Lymphoma
ibrutinib
Sensitive
:
C3
KMT2D mutation
Marginal Zone Lymphoma
ibrutinib
Resistant
:
C3
KMT2D mutation
CRC
Immunotherapy
Sensitive
:
C3
KMT2D mutation
NSCLC
Immunotherapy
Sensitive
:
C3
KMT2D mutation
CRC
Immunotherapy
Sensitive
:
C3
KMT2D mutation
CLL
decitabine
Sensitive
:
D
KMT2D mutation
CLL
chidamide
Sensitive
:
D
KMT2D mutation
CLL
ibrutinib + chidamide
Sensitive
:
D
KMT2D mutation
CLL
ibrutinib + decitabine
Sensitive
:
D
VERI is free for non-commercial use, no login needed.
Content on this site is for research purposes only and is not intended  to be a substitute for medical advice.
For commercial access, including additional premium features, please contact us.
By using VERI, you are agreeing to our